Extrawell Pharmaceutical Holdings (HKSE:00858) ROCE %: -128.35% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Extrawell Pharmaceutical Holdings ROCE %?

Extrawell Pharmaceutical Holdings HKSE:00858 ROCE % is -128.35% as of Mar. 2026. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Extrawell Pharmaceutical Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was -128.35%.

Extrawell Pharmaceutical Holdings  (HKSE:00858) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Extrawell Pharmaceutical Holdings ROCE % Related Terms

Extrawell Pharmaceutical Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Extrawell Pharmaceutical Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Extrawell Pharmaceutical Holdings ROCE % Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.65 11.39 -10.55 18.36 -94.46

Extrawell Pharmaceutical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.70 17.60 19.16 -70.34 -128.35

Extrawell Pharmaceutical Holdings ROCE % Calculation

Extrawell Pharmaceutical Holdings's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-956.67/( ( (1526.352 - 48.504) + (587.339 - 39.59) )/ 2 )
=-956.67/( (1477.848+547.749)/ 2 )
=-956.67/1012.7985
=-94.46 %

Extrawell Pharmaceutical Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=-1024.658/( ( (1098.039 - 49.1) + (587.339 - 39.59) )/ 2 )
=-1024.658/( ( 1048.939 + 547.749 )/ 2 )
=-1024.658/798.344
=-128.35 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -128.35% mean?
Extrawell Pharmaceutical Holdings (HKSE:00858) has a ROCE % of -128.35% as of Mar. 2026.
Is Extrawell Pharmaceutical Holdings' ROCE % too high?
Extrawell Pharmaceutical Holdings' current ROCE % is -128.35%.
How does Extrawell Pharmaceutical Holdings' ROCE % compare to ZTS?
Extrawell Pharmaceutical Holdings' ROCE % of -128.35% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 6.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 6.55, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 6.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extrawell Pharmaceutical Holdings's current ROCE % is -128.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 68% above its estimated fair value. The current ROCE % is -128.35%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current ROCE % is -128.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Extrawell Pharmaceutical Holdings Business Description

Address 979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.